Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05587049
Other study ID # P23-469
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date November 16, 2023
Est. completion date August 31, 2025

Study information

Verified date April 2024
Source AbbVie
Contact Angela Duarte
Phone +57 1 638-5000
Email angela.duarte@abbvie.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Acute myeloid leukemia (AML) is a cancer of the blood and bone marrow and is the most common acute leukemia in adults. This study will evaluate how well venetoclax in combination with azacitidine works to treat AML in adult participants in Colombia. Venetoclax in combination with azacytidine is approved to treat Acute myeloid leukemia (AML). All study participants will receive venetoclax in combination with azacitidine as prescribed by their study doctor in accordance with approved local label. Adult participants with a new diagnosis of AML will be enrolled. Around 70 participants will be enrolled in the study in Colombia. Participants will receive venetoclax tablets to be taken by mouth in combination with azacitidine given by subcutaneous (SC) or intravenous (IV) injection according to the approved local label. The duration of the study is approximately 36 months. There is expected to be no additional burden for participants in this trial. All study visits will occur during routine clinical practice.


Recruitment information / eligibility

Status Recruiting
Enrollment 70
Est. completion date August 31, 2025
Est. primary completion date August 31, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Newly diagnosed acute myeloid leukemia (AML) defined as participants that have histological confirmation of AML (de novo, secondary) by World Health Organization (WHO) criteria, and have not received any prior treatment for AML. - Ineligible to intensive chemotherapy due to >=75 years of age; or >=18 to 74 years who have comorbidities that preclude use of intensive induction chemotherapy. - Participants starting treatment with venetoclax in combination with azacytidine treated according to the Colombia label and who are not completed the first cycle (Cycle 28 days). Exclusion Criteria: - Participating in an interventional clinical trial within 30 days prior to Venetoclax treatment initiation.

Study Design


Locations

Country Name City State
Colombia Clinica del Country /ID# 248430 Bogota Cundinamarca
Colombia Fundacion Santa Fe de Bogota /ID# 248563 Bogota Cundinamarca
Colombia Coorp Hosp Juan Ciudad Sede Hospital Universitario Mayor Mederi /ID# 248570 Bogota DC Cundinamarca
Colombia Fundacion Valle Del Lili /ID# 248294 Cali Valle Del Cauca
Colombia Hospital Alma Mater de Antioquia /ID# 248562 Medellin Distrito Capital De Bogota
Colombia Hospital Pablo Tobón Uribe /ID# 248569 Medellín
Colombia Sociedad de Oncologia y Hematologia del Cesar /ID# 248615 Valledupar Cesar

Sponsors (1)

Lead Sponsor Collaborator
AbbVie

Country where clinical trial is conducted

Colombia, 

Outcome

Type Measure Description Time frame Safety issue
Primary Overall Survival (OS) OS defined as the time from the date of start Venetoclax to the date of death from any cause. Up to 18 months
Secondary Percentage of Participants Achieving Complete Remission (CR) CR is defined according to the modified International Working Group (IWG) criteria for acute myeloid leukemia (AML) as no morphologic evidence of AML and absolute neutrophil count >=10^3 /µL (>=1.0 x 10^9 /L), platelets >=10^5 /µL (>=100 x 10^9 /L), red blood cell (RBC) transfusion independence, and bone marrow with <5% blasts. Absence of circulating blasts and blasts with Auer rods; absence of extramedullary disease. Up to 18 Months
Secondary Percentage of Participants Achieving Complete Remission with Incomplete Marrow Recovery (Cri) Cri is defined according to the modified IWG criteria for AML as all criteria as CR except for residual neutropenia <10^3 /µL (1,000/ µL), or thrombocytopenia <10^5 /µL (100,000/ µL). If all criteria for CR are meet except for RBC transfusion independence, this also fulfills Cri criteria. Up to 18 Months
Secondary Percentage of Participants Achieving Complete Remission with Incomplete Marrow Recovery (CRh) CRh is defined according to the modified IWG criteria for AML as bone marrow with < 5% blasts and Peripheral blood neutrophil count of > 0.5 × 10^3 /µL and Peripheral blood platelet count of > 0.5 × 10^5 /µL and 1-week (>= 7 days) platelet transfusion-free period prior to the hematology lab collection. Up to 18 Months
Secondary Percentage of Participants Achieving Transfusion Independence Transfusion ndependence is defined as a period of at least 56 days with no transfusion between the first dose of Venetoclax and the last dose of Venetoclax plus 30 days. Up to 18 Months
Secondary Event-Free Survival (EFS) EFS defined as the time from the date of start Venetoclax to the date of morphologic relapse, progressive disease, resistant disease, treatment failure, or death from any cause. Up to 18 Months
Secondary Duration of Remission (DOR) DOR defined as the time from the date of first CR, CRi or CRh to the earliest evidence of morphologic relapse, progressive disease, or death due to disease progression. Up to 18 Months
Secondary Duration of Treatment (DoT) DoT defined as the time from the start of a therapy to the time of treatment discontinuation for any reason. Up to 18 Months
Secondary Percentage of participants with Adverse Events (AE) AE, defined as any unfavorable medical event that is temporarily related to the use of the investigational product, which does not necessarily have a causal relationship with the investigational product. Up to 18 Months
Secondary Percentage of participants achieving Minimal Residual Disease (MRD) negativity MRD negativity, defined as having less than 10^-3 residual blasts per leukocyte measured in the bone marrow. Up to 18 Months
Secondary Change in Health-Related Quality of Life (HRQOL) Score HRQOL score, defined as a multidimensional construct defined as the subjective perception of the life as a whole, including physical, emotional, social, cognitive functions, disease symptoms and side effects of treatment. Up to 18 Months
See also
  Status Clinical Trial Phase
Recruiting NCT05400122 - Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer Phase 1
Recruiting NCT04460235 - Immunogenicity of an Anti-pneumococcal Combined Vaccination in Acute Leukemia or Lymphoma Phase 4
Completed NCT03678493 - A Study of FMT in Patients With AML Allo HSCT in Recipients Phase 2
Completed NCT04022785 - PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Phase 1
Recruiting NCT05424562 - A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy Receiving Oral Venetoclax Tablets in Canada
Completed NCT03197714 - Clinical Trial of OPB-111077 in Patients With Relapsed or Refractory Acute Myeloid Leukaemia Phase 1
Terminated NCT03224819 - Study of Emerfetamab (AMG 673) in Adults With Relapsed/Refractory Acute Myeloid Leukemia (AML) Early Phase 1
Active, not recruiting NCT04070768 - Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax in Patients With Relapsed or Refractory CD33+ Acute Myeloid Leukemia:Big Ten Cancer Research Consortium BTCRC-AML17-113 Phase 1
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Active, not recruiting NCT04107727 - Trial to Compare Efficacy and Safety of Chemotherapy/Quizartinib vs Chemotherapy/Placebo in Adults FMS-like Tyrosine Kinase 3 (FLT3) Wild-type Acute Myeloid Leukemia (AML) Phase 2
Recruiting NCT04385290 - Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC) Phase 1/Phase 2
Recruiting NCT04920500 - Bioequivalence of Daunorubicin Cytarabine Liposomes in Naive AML Patients N/A
Recruiting NCT03897127 - Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy With CPX-351 in Adult Patients With Newly Diagnosed AML and Intermediate- or Adverse Genetics Phase 3
Active, not recruiting NCT04021368 - RVU120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome Phase 1
Recruiting NCT03665480 - The Effect of G-CSF on MRD After Induction Therapy in Newly Diagnosed AML Phase 2/Phase 3
Completed NCT02485535 - Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome After Transplant Phase 1
Enrolling by invitation NCT04093570 - A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose), With a Food Effect Substudy at Select Study Centers Phase 2
Recruiting NCT04069208 - IA14 Induction in Young Acute Myeloid Leukemia Phase 2
Recruiting NCT05744739 - Tomivosertib in Relapsed or Refractory Acute Myeloid Leukemia (AML) Phase 1
Recruiting NCT04969601 - Anti-Covid-19 Vaccine in Children With Acute Leukemia and Their Siblings Phase 1/Phase 2

External Links